Organon

Yahoo Finance • 3 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Roivant Sciences VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Orga... Full story

Yahoo Finance • 4 months ago

Roth analysis: Has volatility created a trigger warning for stocks?

Investing.com - The financial markets have experienced a roller coaster ride of late, prompting analysts at Roth to issue a technical strategy update. Despite ending last week down just 0.04%, the S&P 500's minor dip feels like a victory... Full story

Yahoo Finance • 8 months ago

12 Under-the-Radar Stocks With Massive Upside for 2024

In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024. If you want to skip our overview of shareholder ownership and how shares can jump if they come 'over' the radar instead of under, then you ca... Full story

Yahoo Finance • 8 months ago

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 8 months ago

15 Best Affordable Dividend Stocks To Invest In Right Now

In this article, we will take a detailed look at the 15 Best Affordable Dividend Stocks To Invest In Right Now. For a quick overview of such stocks, read our article5 Best Affordable Dividend Stocks To Invest In Right Now. When Meta Platf... Full story

Yahoo Finance • 10 months ago

13 Best Pharma Dividend Stocks To Buy in 2024

In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024. Within the healt... Full story

Yahoo Finance • 11 months ago

Organon & Co (OGN) Fell on Missed Consensus

Miller Value Partners, an investment management company, released its “Income Strategy” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 11.07% net of fees versus... Full story

Yahoo Finance • last year

13 Best Low-Priced Dividend Stocks To Invest In

In this article, we will take a detailed look at the13 Best Low-Priced Dividend Stocks To Invest In. For a quick overview of such stocks, read our article 5 Best Low-Priced Dividend Stocks To Invest In. Stocks rebounded sharply in 2023 de... Full story

Yahoo Finance • last year

Top 20 Drug Companies in the US by Revenue

In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which d... Full story

Yahoo Finance • last year

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®

sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued groupFiling acceptance reinforces Sams... Full story

Yahoo Finance • last year

14 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds

In this article, we discuss the 14 most undervalued healthcare stocks to buy according to hedge funds. To skip the detailed analysis of the healthcare industry, go directly to the 5 Most Undervalued Healthcare Stocks To Buy According To He... Full story

Yahoo Finance • last year

3 Pharmaceutical Stocks That Are Too Cheap to Ignore

On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. Viatris (NASDAQ: VTRS), GSK (NYSE: GSK), and Organon (NYSE: OGN) are too inexpensive to pass up at this point. Let's look at some other... Full story

Yahoo Finance • last year

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vagina... Full story

Yahoo Finance • 2 years ago

20 Worst Performing S&P 500 Stocks in 2023

In this article, we discuss 20 worst performing S&P 500 stocks in 2023. If you want to skip our detailed analysis of the stock market outlook, skip over to 5 Worst Performing S&P 500 Stocks in 2023. Wall Street analysts are still largely... Full story

Yahoo Finance • 2 years ago

11 Best Mid-Cap Healthcare Stocks To Buy Now

In this article, we discuss 11 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Mid-Cap Healthcare Stocks To Buy Now. The healthcare industry outlook is currently uncertain due... Full story

Yahoo Finance • 2 years ago

13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds

In this article, we will take a look at the 13 most undervalued healthcare stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds. According... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).  Such investors are advised to contact Robert S. Willoughby at newaction@... Full story

Yahoo Finance • 2 years ago

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DAR... Full story

Yahoo Finance • 2 years ago

Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s h... Full story

Yahoo Finance • 3 years ago

ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagol... Full story